© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
August 05, 2021
The executive director of Banner Alzheimer’s Institute discussed the current state of AD trials, as well as his perspective on ongoing efforts to establish prevention therapies.
Led by a team of the top talents, NYU Langone’s Comprehensive Epilepsy Center’s contributions to drug development and improving the quality of life for patients stands alone.
August 04, 2021
Preliminary results showed that a fusion of accelerometry and blood volume post modalities achieved the best AUC-ROC for 9 combined seizure types.
Results and safety data from the phase 1/2 study of the therapy for Hunter syndrome/MPS II were presented at MPS 2021, the 18th International Symposium on MPS and Released Diseases, on July 25.
The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
Among independent variables including DMT group, time from COVID-19 infection, total IgG level, age, sex, obesity, and COVID-19 severity, only the anti-CD20 group was associated with decreased odds of positive serology.
The president of the American Heart Association discussed the necessary steps to increase access to systems of care in order to improve health overall, including the integration of telemedicine.
The chief medical officer of Cortexyme discussed the company’s investigational agent atuzaginstat, its mechanism of action, and the findings of the phase 2/3 GAIN trial.
August 03, 2021
The model discovered nonsequential, overlapping disease progression trajectories, supporting the use of nondeterministic disease progression models.
Cummings and colleagues presented appropriate use criteria for the newly approved Biogen/Eisai agent at the 2021 Alzheimer’s Association International Conference.